Ascendia Pharmaceuticals, a specialty pharmaceutical company engaged in nano-formulation design, formulation, and manufacture of poorly soluble molecules, announced that it has entered into a collaboration with KC Pharmaceuticals for the development of five over-the-counter (OTC) sterile ophthalmic drop medicines.
KC Pharmaceuticals will leverage Ascendia’s formulation development and analytical testing capabilities to develop these new products. KC Pharmaceuticals will leverage its manufacturing and distribution expertise to commercialize the products.
Ascendia specializes in improving the bioavailability of poorly water soluble drugs using its nano-particle and nano-emulsion based technologies. Ascendia formulates products for injection (IV, SC or IM); transdermal, ophthalmic or nasal delivery; and both immediate-release and controlled-release products for oral administration. The company based in North Brunswick, New Jersey (USA) has three technology platforms – EmulSol for producing nano-emulsions, AmorSol for creating amorphous solid dispersions, and NanoSol for formulating nano-particles.
KC Pharmaceuticals operates in Pomona (California, USA) manufactures, fabricates, and processes of drugs for human and veterinary use. Company offers contract ophthalmic product manufacturing services.